Vasculitis & polymyalgia rheumatica
Rituximab as maintenance therapy for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials
Authors' conclusion
According to these results, it appears that the 84-month remission rate is higher with an 18-month fixed RTX regimen compared with AZA and 18-month tailored RTX. Also, extending RTX to 36 months does not appear to reduce the long-term relapse rate compared with the 18-month fixed RTX regimen.
Study context
- Population
- Patients with AAV who achieved a complete remission after induction therapy
- Participants
- 58 / 97 / 40 / 42 / 41
- Comparison
- AZA vs 18-month fixed-schedule rituximab (RTX) vs 18-month tailored RTX vs 36-month RTX (tailored/fixed or fixed/fixed) as maintenance
- AZAn = 58
- 18-month fixed-schedule RTXn = 97reference
- 18-month tailored-RTXn = 40
- 36-month tailored/fixed RTXn = 42
- 36-month fixed/fixed RTXn = 41
- Outcome
- Relapse-free survival
- Follow-up
- Month 84
Methodological detailsprospective long-term follow-up through month 84, adjusted for prognostic factors
- Prospective long-term follow-up through month 84
- Adjusted for prognostic factors
Pooled result
As reported in the abstract
Major relapse
Hazard ratio (95% CI)
18-month fixed-schedule RTXvs AZAadjusted for prognostic factors
0.38(0.20–0.71)
18-month tailored-RTXvs 18-month fixed-schedule RTX
2.92(1.43–5.96)
36-month fixed/fixed RTXvs 18-month fixed-schedule RTXrisk similar
0.69(0.38–1.25)
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials. Ann Rheum Dis. Published 11 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →